Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
UBS
Cerilliant
Cipla
Fuji
AstraZeneca
McKesson
Harvard Business School
US Department of Justice
Colorcon

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,143,241

« Back to Dashboard

Which drugs does patent 8,143,241 protect, and when does it expire?


Patent 8,143,241 protects RUBRACA and LYNPARZA and is included in three NDAs.

This patent has seventy-two patent family members in thirty-six countries.

Summary for Patent: 8,143,241

Title:DNA damage repair inhibitors for treatment of cancer
Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Inventor(s): Ashworth; Alan (London, GB), Jackson; Stephen (Cambridge, GB), Martin; Niall (Cambridge, GB), Smith; Graeme (Cambridge, GB), O'Connor; Mark (Cambridge, GB)
Assignee: Kudos Pharmaceuticals Limited (Cambridge, GB) The Institute of Cancer Research (London, GB)
Application Number:11/245,735
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-001Aug 17, 2017RXYesNo► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
TABLET;ORAL208558-002Aug 17, 2017RXYesYes► Subscribe► Subscribe
Astrazeneca Pharms
LYNPARZA
olaparib
CAPSULE;ORAL206162-001Dec 19, 2014RXYesYes► Subscribe► Subscribe TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,143,241

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,912,187Phthalazinone derivatives► Subscribe
7,449,464Phthalazinone derivatives► Subscribe
7,981,889Phthalazinone derivatives► Subscribe
8,071,579DNA damage repair inhibitors for the treatment of cancer► Subscribe
9,169,235Phthalazinone derivatives► Subscribe
7,662,818Phthalazinone derivatives► Subscribe
9,566,276Phthalazinone derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,143,241

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine94209► Subscribe
TaiwanI338000► Subscribe
Taiwan200530196► Subscribe
TaiwanI336694► Subscribe
Taiwan200505871► Subscribe
Slovenia1633724► Subscribe
Singapore150548► Subscribe
Russian Federation2010149166► Subscribe
Russian Federation2413515► Subscribe
Russian Federation2006121459► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Chinese Patent Office
Johnson and Johnson
Cantor Fitzgerald
Chubb
Covington
US Army
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot